NCT00327665 - Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population | Biotech Hunter

Enrollment

335

Participants

Timeline

Start Date

May 1, 2006

Primary Completion Date

January 1, 2007

Study Completion Date

January 8, 2007

Conditions

Infections, Streptococcal

Interventions

BIOLOGICAL

11-valent pneumococcal vaccine GSK513026

Two-dose intramuscular injection. Each group receiving one of the 3 formulations

BIOLOGICAL

Pneumo 23™

Single-dose intramuscular injection.

BIOLOGICAL

Placebo

1 intramuscular injection.

BIOLOGICAL

10-valent pneumococcal vaccine GSK513026

Two-dose intramuscular injection

Trial Locations (3)

GSK Investigational Site, Ghent

GSK Investigational Site, Pirkkala

GSK Investigational Site, Uppsala